2X2 FACTORIAL STUDY TO EVALUATE EFFECTS OF LANTUS (INSULIN GLARGINE)

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 ORIGIN研究将评估IGT、IFG和早期2型糖尿病患者（大血管事件风险高）是否可以安全地使用甘精胰岛素治疗至接近正常血糖水平。 据推测，与对照组相比，这种治疗将降低他们未来发生大血管和微血管事件的风险，对照组将根据正常指南进行随访和治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ORIGIN Study will evaluate whether people with IGT, IFG, and early type 2 diabetes who are at high risk for macrovascular events can be safely treated wih insulin glargine to near normal levels of blood glucose. It is hypothesized that this treatment will reduce their risk for future macrovascular and microvascular events compared to a control group who will be followed and treated according to normal guidelines.